Evidence map›Paper›PMID 39950976›Full record

ArticleThe Journal of clinical endocrinology and metabolism2025

Machine Learning-Based Survival Prediction Tool for Adrenocortical Carcinoma.

Emre Sedar Saygili, Yasir S Elhassan, Alessandro Prete, Juliane Lippert, Barbara Altieri, Cristina L Ronchi

Abstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Machine Learning-Based Survival Prediction Tool for Adrenocortical Carcinoma.The Journal of clinical endocrinology and metabolism · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emre Sedar SaygiliDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale 17020, Turkey.
Yasir S ElhassanDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.
Alessandro PreteDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.ORCID 0000-0002-4821-0336
Juliane LippertInstitute of Human Genetics, University of Wuerzburg, 97070 Wuerzburg, Germany.
Barbara AltieriDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany.ORCID 0000-0003-2616-3249
Cristina L RonchiDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.ORCID 0000-0001-5020-2071

Funding

EU COST Action CA20122The Society of Endocrinology and Metabolism of Türkiye
6 · The paper itself

Abstract

contextAdrenocortical carcinoma (ACC) is a rare, aggressive malignancy with difficult to predict clinical outcomes. The S-GRAS score combines clinical and histopathological variables (tumor stage, grade, resection status, age, and symptoms) and showed good prognostic performance for patients with ACC.

objectiveTo improve ACC prognostic classification by applying robust machine learning (ML) models.

methodWe developed ML models to enhance outcome prediction using the published S-GRAS dataset (n = 942) as the training cohort and an independent dataset (n = 152) for validation. Sixteen ML models were constructed based on individual clinical variables. The best-performing models were used to develop a web-based tool for individualized risk prediction.

resultsQuadratic Discriminant Analysis, Light Gradient Boosting Machine, and AdaBoost Classifier models exhibited the highest performance, predicting 5-year overall mortality (OM), and 1-year and 3-year disease progression (DP) with F1 scores of 0.79, 0.63, and 0.83 in the training cohort, and 0.72, 0.60, and 0.83 in the validation cohort. Sensitivity and specificity for 5-year OM were at 77% and 77% in the training cohort, and 65% and 81% in the validation cohort, respectively. A web-based tool (https://acc-survival.streamlit.app) was developed for easily applicable and individualized risk prediction of mortality and disease progression.

conclusionS-GRAS parameters can efficiently predict outcome in patients with ACC, even using a robust ML model approach. Our web app instantly estimates the mortality and disease progression for patients with ACC, representing an accessible tool to drive personalized management decisions in clinical practice.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaMachine LearningAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisRisk Assessmentadrenal cancermodelmortalityprecision medicineprognosis

Identifiers

PMID39950976
PMCPMC12448644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.